Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Innate Pharma’s Cancer Drug Misses Endpoint in Phase 2 AML Study

By Ryan Bushey | February 6, 2017

Innate Pharma, a French biotech firm, reported on Monday its experimental lead cancer drug lirilumab missed its primary endpoint in a Phase 2 study. 

Lirilumab is a monoclonal antibody being tested as a checkpoint inhibitor designed to block the interaction between the KIR2DL-1,-2,-3 inhibitory receptors and their ligands, according to the company’s announcement. The idea behind this mechanism of action would spur the activation of natural killer cells and some subsets of T cells potentially facilitating a more potent attack on cancer cells. 

Investigators running this randomized, double-blind, placebo-controlled trial recruited 150 elderly patients diagnosed with acute myeloid leukemia (AML). The goal was to gage lirilumab’s efficacy as a single agent for treating this form of blood cancer. 

Results indicated there was no statistically significant difference between the lirilumab arms of the study and the placebo-controlled group for improving leukemia-free survival or similar efficacy endpoints. Any occurence of adverse events were in line with previously reported safety profiles of the drug as well. 

“Although we knew that this setting was challenging, we are disappointed by the results of the EffiKIR study and will investigate further to better understand the data in its entirety,” said Innate’s Chief Medical Officer Pierre Didion in a statement. 

Innate will continue to test lirilumab in conjuction with Bristol-Myers Squibb’s Opdivo in six other clinical trials. In 2011, Bristol-Myers struck a $35 million deal with Innate to gain worldwide rights to their lead candidate with the potential for money based on lirilumab acheiveing certain milestone goals throughout the development process. 


Filed Under: Drug Discovery

 

Related Articles Read More >

lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study
artificial intelligence
Defining complexity: A framework to identify complex clinical trials and set them up for success

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50